Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The role of FDG-PET plus whole body MRI in staging patients with high-risk SMM & R/R myeloma

Claudio Cerchione • 28 Sep 2023
IMS 2023
Multiple Myeloma Rare Diseases Smoldering Myeloma

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy, evaluates the utilization of FDG-PET plus whole body MRI scans in the staging of patients with high-risk smoldering multiple myeloma (HR-SMM) and relapsed/refractory (R/R) multiple myeloma. Dr Cerchione elaborates on how these scans can aid in anticipating relapses and disease progression. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Claudio Cerchione

6:48
Key trials in multiple myeloma presented at ASH 2023: take home messages
Claudio Cerchione • 11 Dec 2023
4:58
Novel immunotherapies transforming R/R myeloma treatment: bispecifics, CAR-T cells & more
Claudio Cerchione • 28 Sep 2023
3:15
Promising triplets and agents in R/R myeloma: SVd, Isa-Kd and melflufen
Claudio Cerchione • 28 Sep 2023
3:32
Potential applications of artificial intelligence in myeloma
Claudio Cerchione • 28 Aug 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals